Paclitaxel and filgrastim for hematopoietic progenitor cell mobilization in patients with hematologic malignancies after failure of a prior mobilization regimen

Trevor McKibbin, Julianna Burzynski, Rebecca Greene, Jose Ochoa-Bayona, T. W. Tsai, Natalie Callander, Cesar Freytes

Research output: Contribution to journalArticle

3 Scopus citations


Paclitaxel and G-CSF have been evaluated for HPC mobilization in breast cancer and found to have tolerable toxicity with a predictable time to initiate leukapheresis. However, this approach has not been reported in patients with hematologic malignancies failing prior mobilization. We report a case-series of 26 adults given paclitaxel and G-CSF for HPC mobilization after failure of an initial mobilization. Patients received paclitaxel 250 mg/m2 followed by G-CSF 10-16 mcg/kg/day. Compared to the initial regimen, paclitaxel mobilization produced greater CD34+ cell yields (median 1.53×106 CD34+ cells/kg vs. 0.79×106 CD34+ cells/kg, p=0.004). Seventy-six percent of patients initiated leukapheresis on day 8, the remainder on day 9 or 10. Three patients developed febrile neutropenia resulting in one death prior to leukapheresis. Overall, 73% of patients proceeded with autologous HPC transplant. This case-series suggests paclitaxel may be an option for HPC mobilization in patients failing prior regimens.

Original languageEnglish (US)
Pages (from-to)2360-2366
Number of pages7
JournalLeukemia and Lymphoma
Issue number12
Publication statusPublished - Dec 1 2007



  • Hematopoietic stem cell
  • Leukapheresis
  • Marrow and stem cell transplantation
  • Paclitaxel
  • Stem cell mobilization

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this